Budesonide (controlled ileal release)
Treatment for Crohn's Disease
Typical Dosage: 9 mg oral daily for 8 weeks, then taper
Effectiveness
60%
Safety Score
50%
Clinical Trials
30
Participants
4K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
9 mg oral daily for 8 weeks, then taper
Time to Effect
2-4 weeks
Treatment Duration
8-12 weeks
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
80%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$750
Monitoring:$450
Side Effect Mgmt:$100
Total Annual:$1,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.01
Outcome-Based Costs
Cost per Responder
$2,364
Cost per Remission
$3,250
Budesonide (controlled ileal release) Outcomes
for Crohn's Disease
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+55%
Remission Rate
+40%
Common Side Effects
Headache
+15%
Nausea
+8%
Acne
+7%
Adrenal suppression
+15%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov